Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agennix has received a patent no 7,901,879 covering the use of oral human lactoferrins, including talactoferrin, for the treatment of non-small cell lung cancer (NSCLC) and renal cell carcinoma.
Subscribe to our email newsletter
The new US patent entitled, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ would provide protection until 2023.
Agennix chief financial officer Torsten Hombeck said this patent further strengthens their intellectual property position for talactoferrin in a key market and, importantly, covers the use of talactoferrin in its lead indication, non-small cell lung cancer.
"We are pleased to have recently completed enrollment in the FORTIS-M Phase III registration trial evaluating talactoferrin for this use," Hombeck said.